drugset / Trial / NCT04421560
Pembrolizumab, Ibrutinib and Rituximab in PCNSL
NaSingle-groupOpen-labelTreatment
Summary
This research study is evaluating a combination therapy of 3 drugs as possible treatments for recurrent primary central nervous system lymphoma (PCNSL). The three drugs being used in the study are: * Pembrolizumab (MK3475) * Ibrutinib * Rituximab (or biosimilar)
Timeline
- Start
- 2020-08-01
- Primary completion
- 2026-12-05
- Completion
- 2027-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ibrutinib | Small molecule | 560 mg | Oral |
| Subject | Ibrutinib | Small molecule | 840 mg | Oral |
| Subject | Pembrolizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Rituximab | Monoclonal antibody | 375 mg/m2 | Intravenous |